FUSION PHARMACEUTICALS
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT06909825
- Locations
- 🇦🇺
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇦🇺Icon Cancer Centre North Lakes, North Lakes, Queensland, Australia
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06402331
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Hoag Health Center Irvine, Irvine, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
- Conditions
- Advanced Solid TumorNon-small Cell Lung CancerMetastatic Colorectal CarcinomaHead and Neck Squamous Cell CarcinomaPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06147037
- Locations
- 🇺🇸
Hoag Hospital, Irvine, California, United States
🇺🇸UCLA Medical Center, Santa Monica, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
- Conditions
- Gastric CancerPancreatic Ductal Adenocarcinoma (PDAC)Colorectal CancerSquamous Cell Carcinoma of Head and NeckNeuroendocrine Differentiated (NED) Prostate CancerEwing SarcomaNTSR1 Expressing Solid Tumours
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05605522
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Hoag Family Cancer Institute, Newport Beach, California, United States
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
- Conditions
- Bladder CarcinomaHead and Neck Squamous Cell CarcinomaSusceptible FGFR3 Genetic AlterationsBreast CancerFGFR3 ReceptorFGFR3 Protein OverexpressionColorectal CancerLiver CancerAdvanced Solid TumorFGFR3
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Fusion Pharmaceuticals Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05363605
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Prev
- 1
- 2
- Next
News
Radiopharmaceuticals: The Next Frontier in Precision Oncology as Big Pharma Competes for Market Share
Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.
Biopharma M&A Activity Reaches $79.4 Billion in 2024 Despite 50% Drop from Previous Year
Biopharma M&A activity totaled $79.4 billion in 2024, representing approximately half of 2023's total value, though deal volume saw a slight increase when excluding four mega-deals from the previous year.
Pharmaceutical R&D Highlights of 2024: GLP-1s, CRISPR, and More
• GLP-1 receptor agonists like semaglutide and tirzepatide showed potential beyond diabetes and weight loss, including cardiovascular and mental health benefits. • CRISPR gene editing entered the market with Casgevy for sickle cell disease and β-thalassemia, though uptake has been slow due to complex treatment requirements. • Protein-folding algorithms developed by Nobel laureates revolutionized biochemical research and found applications in pharmaceutical drug discovery. • Antibody-drug conjugates (ADCs) saw major investment, with firms focusing on novel linker chemistries to enhance their efficacy and target specificity.